All rights reserved. No part of this guideline may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, or in any information storage or retrieval system, without permission in writing from the National Collaborating Centre for Mental Health. Enquiries in this regard should be directed to the Centre Administrator: ku.ca.hcyspcr@nimdAHMCCN
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Collaborating Centre for Mental Health (UK). Bipolar Disorder: The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. London: The British Psychological Society and The Royal College of Psychiatrists; 2014 Sep. (NICE Clinical Guidelines, No. 185.)
April 2018: Footnotes and cautions have been added and amended to link to the MHRA's latest advice and resources on sodium valproate. Sodium valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place. This is because of the risk of malformations and developmental abnormalities in the baby. November 2017: Footnotes for some recommendations were updated with current UK marketing authorisations and MHRA advice. Links to other guidelines have also been updated. Some research recommendations have been stood down. See these changes in the short version of the guideline.
![Cover of Bipolar Disorder](/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-nicecg185-lrg.png)
Bipolar Disorder: The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care.
Show detailsAbbreviations
- AUS
Australia
- BEL
Belgium
- BGR
Bulgaria
- BPI
bipolar I
- CHN
China
- DEU
Germany
- Dur
duration in months
- Freq
frequency
- HKG
Hong Kong
- IND
India
- IRN
Iran, Islamic Republic of
- ISR
Israel
- JPN
Japan
- KOR
Korea
- N Rand
number of participants randomised
- N Post
number of participants at post-treatment
- NR
not reported
- PHL
Philippines
- RUS
Russian Federation
- TMS
transcranial magnetic stimulation
- TWN
Taiwan
- UKR
Ukraine
- USA
United States
- ZAF
South Africa
1.1. Pharmacological Interventions
Study1 | Country | Age | % Female | % BPI | Concomitant medication | N Rand | N Post | Group | Dose | Freq | Dur |
---|---|---|---|---|---|---|---|---|---|---|---|
Pharmacological interventions | |||||||||||
CIPRIANI2011 | NR | NR | NR | NR | NR | 1,284 | NR | Aripiprazole | 30-50 mg | NR | 3-6 |
379 | NR | Asenapine | 10-20 mg | NR | 3 | ||||||
315 | NR | Carbamazepine | 200-1,600 mg | NR | 2-6 | ||||||
59 | NR | Gabapentin | 600-3,600 mg | NR | 3 | ||||||
1,101 | NR | Haloperidol | 2-80 mg | NR | 2-6 | ||||||
174 | NR | Lamotrigine | 50-100 mg | NR | 3-6 | ||||||
912 | NR | Lithium | 28-1,800 mg | NR | 3-6 | ||||||
1,927 | NR | Olanzapine | 2-30 mg | NR | 3-6 | ||||||
692 | NR | Paliperidone | 3-12 mg | NR | 3-6 | ||||||
5,139 | NR | Placebo | N/A | NR | 3-6 | ||||||
832 | NR | Quetiapine | 200-800 mg | NR | 3-4 | ||||||
740 | NR | Risperidone | 1-6 mg | NR | 3-4 | ||||||
802 | NR | Topiramate | 50-600 mg | NR | 3 | ||||||
916 | NR | Valproate | 500-2,500 mg | NR | 3-4 | ||||||
1,033 | NR | Ziprasidone | 40-160 mg | NR | 3 |
Study | Country | Age | % Female | % BPI | Concomitant medication | N Rand | N Post | Group | Dose | Freq | Dur |
---|---|---|---|---|---|---|---|---|---|---|---|
Pharmacological interventions | |||||||||||
KANBA2012 | CHN, HKG, JPN, PHL, TWN | 38 | 59% | 100% | Short-acting benzodiazepine and anti-anxiety agents allowed | 128 | 122 | Aripiprazole | 20 mg | 7 | 3 |
130 | 125 | Placebo | N/A | 7 | 3 | ||||||
SZEGEDI2012 | AUS, IND, KOR, RUS, THA, USA | 39 | 69% | 100% | Lithium or valproate. Benzodiazepines allowed | 159 | 155 | Asenapine | 12 mg | 7 | 12 |
167 | 163 | Placebo | N/A | 7 | 12 | ||||||
ASTRAZENECA2011 | BEL, BGR, DEU, IND, RUS, UKR, ZAF | 38 | 38% | 100% | NR | 173 | 173 | Lithium and quetiapine | 450 mg/300 mg | 14 | 6 |
183 | 176 | Placebo and quetiapine | 300 mg | 14 | 6 |
1.2. Nutritional Interventions
Study | Country | Age | % Female | % BPI | Concomitant medication | N Rand | N Post | Group | Dose | Freq | Dur |
---|---|---|---|---|---|---|---|---|---|---|---|
Nutritional interventions | |||||||||||
Omega-3 fatty acids compared with placebo | |||||||||||
CHIU2005 | CHN | NR | NR | 100% | Carbamazepine, lithium or valproate | NR | NR | Eicosapentaenoic acid and docosahexaenoic acid | 440 mg/240 mg | 14 | 4 |
NR | NR | Placebo | N/A | 14 | 4 | ||||||
Folic acid compared with placebo | |||||||||||
BEHZADI2009 | IRN | 35 | 70% | 100% | Valproate | 44 | 41 | Folic acid | 3 mg | 7 | 3 |
44 | 43 | Placebo | N/A | 7 | 3 |
1.3. Physical Interventions
Study | Country | Age | % Female | % BPI | Concomitant medication | N Rand | N Post | Group | Dose | Freq | Dur |
---|---|---|---|---|---|---|---|---|---|---|---|
Physical interventions | |||||||||||
Acupuncture compared with sham acupuncture | |||||||||||
DENNEHY2009A | USA | 37 | 55% | 60% | Medication as usual | 10 | 5 | Acupuncture | N/A | 2 | 5 |
10 | 7 | Sham | N/A | 2 | 5 | ||||||
Transcranial magnetic stimulation (TMS) compared with sham TMS | |||||||||||
KAPTSAN2003 | ISR | 42 | 53% | 100% | Medication as usual | 16 | 11 | TMS | 20 minutes | 7 | 2 |
9 | 8 | Sham | 20 minutes | 7 | 2 |
Footnotes
- 1
Studies are listed alphabetically by drug (group).
- Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care (NICE guideline CG38)
- Surveillance report 2017: Bipolar disorder: assessment and management (2014) NICE guideline CG185
- NICE Clinical Guideline 185: Bipolar disorder: assessment and management
- Interventions for Mania - Study Characteristics - Bipolar DisorderInterventions for Mania - Study Characteristics - Bipolar Disorder
- Cardiovascular Disease - Clearing the SmokeCardiovascular Disease - Clearing the Smoke
- Spinal Muscle Atrophy - StatPearlsSpinal Muscle Atrophy - StatPearls
- Microbe sample from candidate division CPR1 bacterium ADurb.Bin160Microbe sample from candidate division CPR1 bacterium ADurb.Bin160biosample
- BioSample links for Nucleotide (Select 1167320610) (1)BioSample
Your browsing activity is empty.
Activity recording is turned off.
See more...